Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting

No Items In Cart
In recent seminars in Hyderabad and Ahmedabad, India, West’s Tibor Hlobik discussed the challenges faced by injectable drug manufacturers to minimize risk, accelerate product development, ensure patient safety and improve ease of administration. Similar seminars were held in China and Korea.
“Companies must differentiate their new products within therapeutic categories that are very competitive,” said Hlobik. “Prefillable syringes and cartridges offer many benefits as compared to vial formats, including precise dose accuracy, less drug overfill for lower unit cost, and drug product differentiation.”
West organized the seminar to discuss innovative solutions on prefilled syringe, cartridge and safety devices. Hlobik shared his in-depth knowledge and experience in elastomeric components and accessories to support new applications. The presentation also emphasized minimizing risk by selecting the modern formulations, ready-to-use sterile components and 100% vision verification for stringent quality requirements.
Topics discussed included:
More than 80 representatives from leading pharmaceutical companies, especially in injectable dosage, participated in the seminar in Hyderabad.
NovaPure, NovaGuard, Westar and FluroTec are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. FluroTec technology is licensed from Daikyo Seiko, Ltd.
West seeks partners for the NovaGuard SA technology platform as an integrated system. Final assembly is completed by the pharmaceutical company.